<?xml version="1.0" encoding="UTF-8"?>
<p>Severe acute respiratory syndrome (SARS) coronavirus (CoV)‐2 is the seventh member of the CoV family that can infect humans [
 <xref rid="ene14278-bib-0001" ref-type="ref">1</xref>]. Speculation about the neuroinvasive potential of SARS‐CoV‐2 is sustained by reports about neurological signs and symptoms in some COVID‐19‐infected patients [
 <xref rid="ene14278-bib-0002" ref-type="ref">2</xref>]. It remains speculative as to whether these clinical observations are related to infectious or parainfectious nervous system complications as cases with confirmation of SARS‐CoV‐2 and markers of inflammation in cerebrospinal fluid are scarce. The medical efforts during the initial outbreak of the novel CoV‐2 disease (COVID)‐19 were certainly dictated by severe respiratory symptoms and the limited hospital capacities for critically ill patients [
 <xref rid="ene14278-bib-0003" ref-type="ref">3</xref>]. Moreover, the challenges for preventive and protective measures in the healthcare system were multifaceted and tied up resources.
</p>
